Article information
Full text is only aviable in PDF
REFERENCES
[1]
AL Katzenstein, JL Myers.
Pulmonary fibrosis: clinical relevance of pathologic classification.
Am J Resp Crit Care Med, 157 (1998), pp. 1301-1315
[2]
JA Bjoraker, JH Ryu, MK Edwin, et al.
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 157 (1998), pp. 199-203
[3]
American Thoracic Society.
Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American thoracic Society (ATS), and the European Respiratory Society (ERS).
Am J Resp Crit Care Med, 161 (2000), pp. 646-664
[4]
M Selman, TE King, A Pardo.
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.
Ann Intern Med, 134 (2001), pp. 136-151
[5]
KR Flaherty, WD Travis, TV Colby, et al.
Histopathologic variability in usual and non-specific interstitial pneumonias.
Am J Resp Crit Care Med, 164 (2001), pp. 1722-1727
[6]
H Monagham, A Wells, T Colby, R du Bois, D Hansell, A Nicholson.
Prognostic implications of histological patterns in multiple surgical biopsies from patients with idiopathic interstitial pneumonias.
Chest, 125 (2004), pp. 522-526
[7]
AL Katzestein, DA Zisman, LA Litzky, et al.
Usual interstitial pneumonia: histological study of biopsy and explants specimens.
Am J Surg Pathol, 26 (2002), pp. 1567-1577
[8]
WW Douglas, JH Ryu, DR Schroeder.
Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival.
Am J Resp Crit Care Med, 161 (2000), pp. 1172-1178
[9]
R Ziesche, E Hofbauer, K Wittmann, et al.
A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.
N Engl J Med, 341 (1999), pp. 1264-1269
[10]
A Prasse, KM Müller, C Kurz, H Hamm, JC Virchow Jr.
Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis?.
Eur Respir J, 22 (2003), pp. 906-911
[11]
G Raghu, K Bron, W Bradford, K Starko, P Noble, D Swartz, et al.
A placebo- controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.
N Engl J Med, 350 (2004), pp. 125-133
[12]
RJ Mason, MI Schwartz, GW Hunninghake, RA Musson.
Pharmacological therapy for idiopathic pulmonary fibrosis: past, present and future.
Am J Resp Crit Care Med, 160 (1999), pp. 1771-1777
[13]
G Raghu, WC Johnson, D Lockhart, Y Mageto.
Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study.
Am J Resp Crit Care Med, 159 (1999), pp. 1061-1069
[14]
JJ Silverman, TJ Talbot.
Diffuse interstitial fibrosis camouflaged by hypermetabolism and cardiac failure: antemortem diagnosis with biopsy and catheterization studies.
Ann Intern Med, 38 (1953), pp. 1326-1338
[15]
JH Dark.
Priorities for lung transplantation.
Lancet, 351 (1998), pp. 4-5
[16]
J de Meester, JMA Smits, GG Persijin, et al.
Listing for lung transplantation: life expectancy and transplant effect stratified by type of end-stage lung disease. The Euro Transplant experience.
J Heart Lung Transplant, 20 (2001), pp. 518-525
[17]
N Mogulkoc, MH Brutsche, PW Bishop, M Greaves, AW Horrocks, JJ Egan.
Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation.
Am J Resp Crit Care Med, 164 (2001), pp. 103-108
[18]
BF Meyers, JP Lynch, EP Trulock, et al.
Single vs bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten years institutional experience.
Thorac Cardiovasc Surg, 120 (2000), pp. 99-107
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
